These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31331301)

  • 21. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
    Oberg AL; Heinzen EP; Hou X; Al Hilli MM; Hurley RM; Wahner Hendrickson AE; Goergen KM; Larson MC; Becker MA; Eckel-Passow JE; Maurer MJ; Kaufmann SH; Haluska P; Weroha SJ
    Sci Rep; 2021 Apr; 11(1):8076. PubMed ID: 33850213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing cardiac safety in oncology drug development.
    Seltzer JH; Gintant G; Amiri-Kordestani L; Singer J; Koplowitz LP; Moslehi JJ; Barac A; Yu AF
    Am Heart J; 2019 Aug; 214():125-133. PubMed ID: 31202099
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug development and clinical trial design in pancreatico-biliary malignancies.
    Harrington J; Carter L; Basu B; Cook N
    Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling of human tumor xenografts and dose rationale in oncology.
    Simeoni M; De Nicolao G; Magni P; Rocchetti M; Poggesi I
    Drug Discov Today Technol; 2013 Sep; 10(3):e365-72. PubMed ID: 24050133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vivo Pharmacology Models for Cancer Target Research.
    Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX
    Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
    Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
    Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
    [No Abstract]   [Full Text] [Related]  

  • 29. Modeling Tumor Immunology and Immunotherapy in Mice.
    Buqué A; Galluzzi L
    Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism.
    Henderson CJ; McLaren AW; Kapelyukh Y; Wolf CR
    F1000Res; 2022; 11():1081. PubMed ID: 37065929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.
    Teng Z; Gupta N; Hua Z; Liu G; Samnotra V; Venkatakrishnan K; Labotka R
    Clin Transl Sci; 2018 Mar; 11(2):218-225. PubMed ID: 29168990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo.
    Laajala TD; Corander J; Saarinen NM; Mäkelä K; Savolainen S; Suominen MI; Alhoniemi E; Mäkelä S; Poutanen M; Aittokallio T
    Clin Cancer Res; 2012 Aug; 18(16):4385-96. PubMed ID: 22745104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Porcine cancer models: potential tools to enhance cancer drug trials.
    Robertson N; Schook LB; Schachtschneider KM
    Expert Opin Drug Discov; 2020 Aug; 15(8):893-902. PubMed ID: 32378979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opportunities for Quantitative Translational Modeling in Oncology.
    Yates JWT; Byrne H; Chapman SC; Chen T; Cucurull-Sanchez L; Delgado-SanMartin J; Di Veroli G; Dovedi SJ; Dunlop C; Jena R; Jodrell D; Martin E; Mercier F; Ramos-Montoya A; Struemper H; Vicini P
    Clin Pharmacol Ther; 2020 Sep; 108(3):447-457. PubMed ID: 32569424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trials, tribulations, and trends in tumor modeling in mice.
    Schuh JC
    Toxicol Pathol; 2004; 32 Suppl 1():53-66. PubMed ID: 15209404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.